Proactive Investors - Run By Investors For Investors

Novogen on track to commence phase II trial of brain cancer therapy

GBM brain cancer affects 130,000 annually with 3-5% survival rate.
Novogen on track to commence phase II trial of brain cancer therapy
Phase II study to commence in 2H 2017

Novogen (ASX:NRT, NASDAQ:NVGN) is on track to commence the phase II human trial of its GDC-0084 brain cancer therapy in calendar year 2017.

GDC-0084 is an orally-administered therapy which is under development as a treatment for glioblastoma multiforme (GBM), the most common and most aggressive form of brain cancer.

GBM affects circa 130,000 patients worldwide annually, and has one of the poorest outcomes of any cancer, with only 3-5% of patients alive five years after diagnosis.

The GDC-0084 therapy is designed to inhibit tumour growth by targeting an important biochemical control mechanism that is thought to be critical to the growth of the tumour.

GDC-0084 was licensed by Novogen from Genentech, a member of the Roche Group, in October 2016.

Since the transaction, Novogen has completed the transfer of the FDA Investigational New Drug (IND) application from Genentech to Novogen.

Novogen has also taken possession of around 48.8 kilograms of premanufactured drug substance that had been prepared by Genentech in anticipation of a phase II study.

This material is now being formulated into oral capsules for use in the phase II clinical trial.

The study will be a randomized, two-arm study with 200 patients receiving either GDC-0084 or temozolomide as maintenance therapy after completion of standard radiotherapy treatment.

The primary endpoint of the study will be progression-free survival (PFS), with patients followed for overall survival.

PFS can be considered an acceptable endpoint for approval of oncology drugs by FDA.

Novogen anticipates that the phase II study will commence in the second half of calendar 2017, and will take circa 18 months to reach full recruitment, with PFS data available 12 months thereafter.

View full NRT profile View Profile

Novogen Ltd Timeline

August 05 2015

Related Articles

A paper plane about to be launched with the help of surgical scissors
November 13 2018
The voluntarily-suspended company is progressing an ongoing recapitalisation plan.
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use